– Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed –
–
Walloon biotech iTeos Therapeutics completes a new round of $125 million with historical investors and 5 new leading U.S. funds active in initial public offering (IPO). This is one of the largest
As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical
Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing
Initial clinical data expected in 1H 2021
Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing
Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023
Mont-Saint-Guibert, Belgium, and Tokyo, Japan, January 8th
Belgium – 19 December 2019 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment
Total amount raised in the Series D reaches €47.2 Million.
Mont-Saint-Guibert, Belgium, and Tokyo, Japan, December 16, 2019 – Promethera® Biosciences SA, a global innovator in cell-based medicines
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Gosselies, Belgium and Cambridge, MA – Dec. 12, 2019 – iTeos Therapeutics
- Bringing Innovative Liver-Focused Cell therapies to Japanese Markets -
Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have
Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced
Study highlights potential benefit in rare pediatric orthopedic disorder
Mont-Saint-Guibert, Belgium, October 2, 2019 : Novadip Biosciences (“Novadip” or “the company”), a clinical-stage
